Is now the time to buy this exciting healthcare stock? The post Exciting clinical news for this ASX healthcare stock earns it a buy recommendation appeared first on The Motley Fool Australia.

Lantheus Holdings said on ​Tuesday that the U.S. ‌Food and Drug Administration has extended its review of ​the company's ...

Let's see what is getting investors excited today. The post Why is this ASX 300 stock rocketing 17% today? appeared first on The Motley Fool Australia.

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Researchers have developed a tiny antibody that can find a common cancer protein and make tumors light up during PET scans. In tests with mice, tumors containing the protein EphA2 glowed clearly when ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...

Alzheimer's brain markers, such as tau and amyloid, manifest differently across diverse populations, calling for personalized dementia care.